Early experience with teprotumumab for chronic thyroid eye disease

Farid, 2005, Psychological disturbance in graves ophthalmopathy, Arch Ophthalmol, 123, 491, 10.1001/archopht.123.4.491

Bartley, 2011, Rundle and his curve, Arch Ophthalmol, 129, 356, 10.1001/archophthalmol.2011.29

Strianese, 2018, Efficacy and safety of immunosuppressive agents for thyroid eye disease, Ophthalmic Plast Reconstr Surg, 34, S56, 10.1097/IOP.0000000000001131

Bartalena, 2012, Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy, J Clin Endocrinol Metab, 97, 4454, 10.1210/jc.2012-2389

Smith, 2017, Teprotumumab for thyroid-associated ophthalmopathy, N Engl J Med, 376, 1748, 10.1056/NEJMoa1614949

Douglas, 2020, Teprotumumab for the treatment of active thyroid eye disease, N Engl J Med, 382, 341, 10.1056/NEJMoa1910434

Ediriwickrema, 2018, Orbital decompression for thyroid-related orbitopathy during the quiescent phase, Ophthalmic Plast Reconstr Surg, 34, S90, 10.1097/IOP.0000000000001119

Papageorgiou, 2012, Thyroid-associated periorbitopathy: eyebrow fat and soft tissue expansion in patients with thyroid-associated orbitopathy, Arch Ophthalmol, 130, 319, 10.1001/archopthalmol.2011.1271

Mimura, 2020, Analysis of periorbital soft tissue in thyroid eye disease, Ophthalmic Plast Reconstr Surg, 36, 30, 10.1097/IOP.0000000000001450

Godfrey, 2018, Radiotherapy for active thyroid eye disease, Ophthalmic Plast Reconstr Surg, 34, S98, 10.1097/IOP.0000000000001074